ECM
CLRB icon

ExodusPoint Capital Management’s Cellectar Biosciences CLRB Stock Holding History

ExodusPoint Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-48
Closed -$17K – 2178
2021
Q2 		$17K Sell
48
-25
-34% -$10.8K ﹤0.01% 2256
2021
Q1 		$35K Buy
+73
New +$43.4K ﹤0.01% 2046

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ExodusPoint Capital Management's CLRB Position: Q3 2021 in Review

ExodusPoint Capital Management sold out of Cellectar Biosciences (CLRB) in Q3 2021, closing a stake of 48 shares — an estimated $17K sold.

ExodusPoint Capital Management first reported a position in CLRB in Q1 2021 and held it in 2 quarters. The position peaked at $35K in Q1 2021. 38 funds tracked by Wall St. Rank hold CLRB as of Q3 2021.

  • ExodusPoint Capital Management reported no remaining Cellectar Biosciences position as of Q3 2021 after selling out during the quarter.
  • ExodusPoint Capital Management sold 48 Cellectar Biosciences shares in Q3 2021, an estimated $17K.
  • ExodusPoint Capital Management first reported a position in Cellectar Biosciences in Q1 2021 and held it in 2 quarters.
  • ExodusPoint Capital Management's Cellectar Biosciences position peaked at $35K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.